Apprentice.io provides a technology platform that helps life-science manufacturers turn molecules into medicine. Its Tempo Manufacturing Cloud accelerates the end-to-end drug product lifecycle by connecting distributed teams and sites, enabling shop-floor execution and real-time enterprise-wide visibility. Fifteen of the top 20 U.S. pharmaceutical companies use the platform to accelerate high-quality production across diseases from COVID to cancer. The company is led by CEO Angelo Stracquatanio and is based in Jersey City, NJ. It intends to use the newly raised funds to expand sales, marketing, and customer success functions. The round increased the company's total capital raised to $207M. Apprentice develops virtual collaboration products, including its first product Tandem, a wearable headset designed to enable remote collaboration on the facility floor. The company is based in Jersey City, NJ. It has completed a Series C round of funding of over $100 million. The Series C was led by new investor Alkeon Capital Management. Repeat investors Silverton Partners, Insight Partners, and Pacific Western Bank participated, and Colorcon Ventures made a new investment. The round brings the firm's total funding to $142 million. Apprentice.io delivers a life-sciences industry intelligent manufacturing execution system that helps teams scale faster across small and large molecule, and cell and gene therapy manufacturing. Its cloud-based platform leverages artificial intelligence, augmented reality and Pharma 4.0 to accelerate batch execution and global collaboration. The Apprentice System is an end-to-end platform offering intelligent batch execution, augmented procedures/workflows, predictive resource management, event tracking, remote collaboration and immersive training. The company says its software is helping to increase speed to market on a number of COVID-19 vaccines. Apprentice.io supports Fortune 100 clients and other complex, compliance-driven customers across the U.S., Asia, South America and Europe. Led by CEO and co-founder Angelo Stracquatanio, the company plans to use new funds to continue assisting customers as they ramp up production. Apprentice.io provides an intelligent, regulatory-compliant software platform for life sciences manufacturing that combines batch execution, augmented procedures, guided workflows, predictive resource management, event tracking and immersive training. The platform is enhanced with AI, machine learning and augmented reality and is paired with an AR-enhanced remote collaboration tool called Tandem for secure in-suite assistance and troubleshooting. Tandem enables subject-matter experts to assist operators remotely so sensitive project timelines are maintained and transfers between locations are executed correctly. The company supports Fortune 100 clients and other organizations across the U.S., Asia, South America and Europe. Led by CEO and co-founder Angelo Stracquatanio and based in Jersey City, NY, Apprentice.io raised $7.5M in funding and intends to use the proceeds to scale its mounting efforts. The article does not disclose operating metrics or financing instrument details. Apprentice.io develops a conversational augmented reality and artificial intelligence platform tailored for enterprise workflows in pharma and biotech, including batch records, tech transfer, R&D workflows, training, troubleshooting, and support. The platform is device- and platform-independent, supporting mobile ARKit/ARCore, fully immersive headsets (HoloLens, Magic Leap), and monocular smart glasses for all-day operation. The company operates an in-house research laboratory and highlights integrated industry features and intelligent data-capture for audit-readiness. Apprentice has tripled in size and customer reach, adding numerous Fortune 100 clients across the U.S., Asia, South America and Europe. Financially, the company has raised more than $10 million in total capital to date and announced an $8M Series A. With new capital, Apprentice plans significant product and feature developments, improved intelligent responses, and international partnerships to expand its deployments.

Total raised

$207M

Funding rounds

6

Latest round

Equity

Latest activity

Mar 2023